Trial site
Hadassah Hebrew University Medical Center
Jerusalem, 9112001, IsraelNot linked to an institution yet
- 11running trials
- 2closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 24 trials
- Phase 32 trials
- Phase 2/31 trial
- Phase 41 trial
- Status
- Active, not recruiting8 trials
- Recruiting3 trials
- Completed2 trials
- Lead sponsor
- Janssen Research & Development, LLC3 trials
- Boston Scientific Corporation2 trials
- Gilead Sciences2 trials
- University Hospital, Basel, Switzerland2 trials
- BicycleTx Limited1 trial
- and 3 more
Running trials
Recruiting
Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals
NCT06762730· Phase 4· Hadassah Medical Organization· Source
Contact: Hila Elinav, Doctor
Active, not recruiting
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596· Phase 2· BicycleTx Limited· Source
Recruiting
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
NCT05589714· Jaeb Center for Health Research· Source
Contact: Eyal Banin, MD
Recruiting
Risk of Recurrent CeAD After Pregnancy
NCT06258109· University Hospital, Basel, Switzerland· Source
Contact: Stefan T Engelter, MD
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· Phase 3· Gilead Sciences· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299· Phase 3· Gilead Sciences· Source
Active, not recruiting
EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke
NCT05029414· University Hospital, Basel, Switzerland· Source
Active, not recruiting
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source
Recruiting
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134· Boston Scientific Corporation· Source
Contact: Heleen Scholtes
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error